Regencell Bioscience Holdings Limited (RGC)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 50/100 (MEDIUM), 13.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 1.18% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- How Investors Are Reacting To Regencell Bioscience Holdings (RGC) Wider Full Year Loss
- Is Regencell Bioscience Holdings (RGC) Fully Priced After Its Annual Loss Deepened?
- Auditor Change Puts Regencell Bioscience Governance And Cash Runway In Focus
- Relevant Gold South Pass VTEM Survey Defines Multi-Kilometre Structural Corridors with High Priority Drill Targets
- Taiwan Semiconductor Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks
- Relevant Gold Completes Strategic Financing; Embarks on Largest Drilling Program in Company History
- Relevant Gold Launches Fully Funded 2026 Drill Program and Receives Five-Year BLM Expanded Exploration Permit at Bradley Peak
- Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A). — J Immunother Cancer 2026 Oct 1 PMID 42823088
- Limited evidence of nosocomial MRSA transmission in a low-prevalence tertiary care center: a five-year genomic epidemiology study. — J Hosp Infect 2026 Oct 1 PMID 42822781
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Regencell Bioscience Holdings Limited.
Full RGC Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.